Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Prolonged early G 1 arrest by selective CDK4/CDK6 inhibition sensitizes myeloma cells to cytotoxic killing through cell cycle–coupled loss of IRF4

Xiangao Huang, Maurizio Di Liberto, David Jayabalan, Jun Liang, Scott Ely, Jamieson Bretz, Arthur L. Shaffer, III, Tracey Louie, Isan Chen, Sophia Randolph, William C. Hahn, Louis M. Staudt, Ruben Niesvizky, Malcolm A. S. Moore, Selina Chen-Kiang

Blood (2012) 120 (5): 1095–1106.

https://doi.org/10.1182/blood-2012-03-415984

Published: 2012

Includes: Supplemental data

Journal Articles

Induction of sequential G1 arrest and synchronous S phase entry by reversible CDK4/CDK6 inhibition sensitizes myeloma cells for cytotoxic killing through loss of IRF-4.

Xiangao Huang, PhD, Maurizio Di Liberto, PhD, Scott Ely, MD, MPH, David S Jayabalan, BSMS, Isan Chen, MD, Keith D. Wilner, PhD, Malcolm Moore, DPhil, Ruben Niesvizky, MD, Selina Chen-Kiang, PhD

Blood (2009) 114 (22): 299.

https://doi.org/10.1182/blood.V114.22.299.299

Published: 2009

Journal Articles

A Phase I Trial of PD 0332991, a Novel, Orally-Bioavailable CDK4/6-Specific Inhibitor Administered in Combination with Bortezomib and Dexamethasone to Patients with Relapsed and Refractory Multiple Myeloma.

Ruben Niesvizky, MD, Scott Ely, MD, MPH, David S Jayabalan, Megan C. Manco, Seema Singhal, MD, Mary Crann, Rachel Courtney, Cynthia DuFresne, Keith D. Wilner, PhD, Isan Chen, MD, Tomer Mark, MD, John P. Leonard, MD, Morton Coleman, MD, Maurizio DiLiberto, PhD, Xiangao Huang, PhD, Selina Chen-Kiang, PhD

Blood (2009) 114 (22): 1877.

https://doi.org/10.1182/blood.V114.22.1877.1877

Published: 2009

Journal Articles

Targeting CDK4/6 and the Cell Cycle in Combination with Bortezomib in the 5T33MM Myeloma Model.

Eline Menu, PhD, Josefina Garcia, Ph.D., Xiangao Huang, Ph.D., Maurizio Di Liberto, Ph.D., Peter Toogood, Ph.D., Isan Chen, M.D., Karin Vanderkerken, Ph.D., Selina Chen-Kiang, Ph.D.

Blood (2007) 110 (11): 254.

https://doi.org/10.1182/blood.V110.11.254.254

Published: 2007

Journal Articles

Targeting Cdk4/6 in Combination Therapy Overcomes Proteasome Inhibitor Resistance in Multiple Myeloma through Synergistic Mitochondria Depolarization.

Xiangao Huang, PhD, Tracey Louie, B.Sc., Maurizio Di Liberto, Ph.D., Jun Rice, Ph.D., David Jayabalan, B.Sc., Kang Zhang, B.Sc., Michael Palladino, Ph.D., Isan Chen, M.D., Peter Toogood, Ph.D, Ruben Niesvizky, M.D., Malcolm A.S. Moore, Ph.D., Selina Chen-Kiang, Ph.D.

Blood (2007) 110 (11): 667.

https://doi.org/10.1182/blood.V110.11.667.667

Published: 2007

NARROW

Prolonged early G 1 arrest by selective CDK4/CDK6 inhibition sensitizes myeloma cells to cytotoxic killing through cell cycle–coupled loss of IRF4

Induction of sequential G1 arrest and synchronous S phase entry by reversible CDK4/CDK6 inhibition sensitizes myeloma cells for cytotoxic killing through loss of IRF-4.

A Phase I Trial of PD 0332991, a Novel, Orally-Bioavailable CDK4/6-Specific Inhibitor Administered in Combination with Bortezomib and Dexamethasone to Patients with Relapsed and Refractory Multiple Myeloma.

Targeting CDK4/6 and the Cell Cycle in Combination with Bortezomib in the 5T33MM Myeloma Model.

Targeting Cdk4/6 in Combination Therapy Overcomes Proteasome Inhibitor Resistance in Multiple Myeloma through Synergistic Mitochondria Depolarization.

Email alerts

ASH Publications

American Society of Hematology

Prolonged early G 1 arrest by selective CDK4/CDK6 inhibition sensitizes myeloma cells to cytotoxic killing through cell cycle–coupled loss of IRF4

Induction of sequential G1 arrest and synchronous S phase entry by reversible CDK4/CDK6 inhibition sensitizes myeloma cells for cytotoxic killing through loss of IRF-4.

A Phase I Trial of PD 0332991, a Novel, Orally-Bioavailable CDK4/6-Specific Inhibitor Administered in Combination with Bortezomib and Dexamethasone to Patients with Relapsed and Refractory Multiple Myeloma.

Targeting CDK4/6 and the Cell Cycle in Combination with Bortezomib in the 5T33MM Myeloma Model.

Targeting Cdk4/6 in Combination Therapy Overcomes Proteasome Inhibitor Resistance in Multiple Myeloma through Synergistic Mitochondria Depolarization.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only